Top

Published in:

01-08-2012 | Review

Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?

Authors: Lian-Ming Wu, Jia-Ni Hu, Hai-Yan Gu, Jia Hua, Jie Chen, Jian-Rong Xu

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Abstract

Clinical evidence regarding the value of MRI for therapy responses assessment in breast cancer is increasing. The objective of this study is to compare the diagnostic capability of diffusion-weighted MR imaging (DW-MRI) and contrast-enhanced MR imaging (CE-MRI) to evaluate and predict pathological response in breast cancer patients receiving neoadjuvant chemotherapy (NAC). We performed a meta-analysis of all available studies of the diagnostic performance of DW-MRI or CE-MRI to evaluate and predict pathological response to NAC in patients with breast cancer. We determined sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR−), diagnostic odds ratio (DOR) and constructed summary receiver operating characteristic curves using hierarchical regression models. Methodological quality was assessed by QUADAS tool. Thirty-four studies met the inclusion criteria and involved 1,932 pathologically confirmed patients in total. Methodological quality was relatively high. DW-MRI sensitivity was 0.93 (95 % CI 0.82–0.97) and specificity was 0.82 (95 % CI 0.70–0.90). Overall LR+ was 5.09 (95 % CI 3.09–8.38), LR− was 0.09 (95 % CI 0.04–0.22), and DOR was 55.59 (95 % CI 21.80–141.80). CE-MRI sensitivity was 0.68 (95 % CI 0.57–0.77) and specificity was 0.91 (95 % CI 0.87–0.94). Overall LR+ was 7.48 (95 % CI 5.29–10.57), LR− was 0.36 (95 % CI 0.27–0.48), and DOR was 20.98 (95 % CI 13.24–33.24). Our study confirms that DW-MRI is a high sensitive and CE-MRI is a high specific modality in predicting pathological response to NAC in breast cancer patients. The combined use of DW-MRI and CE-MRI has the potential to improve the diagnostic performance in monitoring NAC. Further large prospective studies are warranted to assess the actual value of this combination in breast cancer preoperative treatment screening.

Mieog JS, van der Hage JA, van de Velde CJ (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94(10):1189–1200PubMedCrossRef

Kaufmann M, von Minckwitz G, Bear HD et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18(12):1927–1934PubMedCrossRef

Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26(5):778–785PubMedCrossRef

Jeruss JS, Mittendorf EA, Tucker SL et al (2008) Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26(2):246–252PubMedCrossRef

Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414–4422PubMedCrossRef

Tardivon AA, Ollivier L, El Khoury C, Thibault F (2006) Monitoring therapeutic efficacy in breast carcinomas. Eur Radiol 16(11):2549–2558PubMedCrossRef

Heldahl MG, Lundgren S, Jensen LR, Gribbestad IS, Bathen TF (2011) Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T? J Magn Reson Imaging. doi:10.1002/jmri.22642

Liu YH, Ye JM, Xu L et al (2011) Effectiveness of dynamic contrast-enhanced magnetic resonance imaging in evaluating clinical responses to neoadjuvant chemotherapy in breast cancer. Chin Med J (Engl) 124(2):194–198

Chenevert TL, Stegman LD, Taylor JM et al (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92(24):2029–2036PubMedCrossRef

10.

Herneth AM, Guccione S, Bednarski M (2003) Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 45(3):208–213PubMedCrossRef

11.

Padhani AR, Liu G, Koh DM et al (2009) Diffusion weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2):102–125PubMed

12.

Lyng H, Haraldseth O, Rofstad EK (2000) Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43(6):828–836PubMedCrossRef

13.

Theilmann RJ, Borders R, Trouard TP et al (2004) Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 6:831–837PubMedCrossRef

14.

Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32(1):2–16PubMedCrossRef

15.

Pickles MD, Gibbs P, Lowry M, Turnbull LW (2006) Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging 24:843–847PubMedCrossRef

16.

Tozaki M, Oyama Y, Fukuma E (2010) Preliminary study of early response to neoadjuvant chemotherapy after the first cycle in breast cancer: comparison of 1H magnetic resonance spectroscopy with diffusion magnetic resonance imaging. Jpn J Radiol 28(2):101–109PubMedCrossRef

17.

Yankeelov TE, Lepage M, Chakravarthy A et al (2007) Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 25:1–13PubMedCrossRef

18.

Whiting P, Rutjes AW, Reitsma JB et al (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25PubMedCrossRef

19.

Rutter CM, Gatsonis CA (2010) A hierarchical regression approach to metaanalysis of diagnostic test accuracy evaluations. Stat Med 20(19):2865–2884CrossRef

20.

Park SH, Moon WK, Cho N et al (2012) Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 22(1):18–25PubMedCrossRef

21.

Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK (2011) The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography. Acta Radiol 52(1):21–28PubMedCrossRef

22.

Fangberget A, Nilsen LB, Hole KH et al (2011) Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol 21(6):1188–1199PubMedCrossRef

23.

Dongfeng H, Daqing M, Erhu J (2012) Dynamic breast magnetic resonance imaging: pretreatment prediction of tumor response to neoadjuvant chemotherapy. Clin Breast Cancer 12(2):94–101

24.

De Los Santos J, Bernreuter W, Keene K et al (2011) Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. Clin Breast Cancer 11(5):312–319PubMedCrossRef

25.

Chen JH, Bahri S, Mehta RS et al (2011) Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology 261(3):735–743PubMedCrossRef

26.

Belli P, Costantini M, Ierardi C et al (2011) Diffusion-weighted imaging in evaluating the response to neoadjuvant breast cancer treatment. Breast J 17(6):610–619PubMedCrossRef

27.

Woodhams R, Kakita S, Hata H et al (2010) Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging—comparison with contrast-enhanced MR imaging and pathologic findings. Radiology 254(2):357–366PubMedCrossRef

28.

Park SH, Moon WK, Cho N et al (2010) Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 257(1):56–63PubMedCrossRef

29.

Sharma U, Danishad KK, Seenu V, Jagannathan NR (2009) Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 22(1):104–113PubMedCrossRef

30.

Moon HG, Han W, Lee JW et al (2009) Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 20(4):636–641PubMedCrossRef

31.

Craciunescu OI, Blackwell KL, Jones EL et al (2009) DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. Int J Hyperthermia 25(6):405–415PubMedCrossRef

32.

Chen JH, Mehta RS, Nalcioglu O, Su MY (2008) Inflammatory breast cancer after neoadjuvant chemotherapy: can magnetic resonance imaging precisely diagnose the final pathological response? Ann Surg Oncol 15(12):3609–3613PubMedCrossRef

33.

Bhattacharyya M, Ryan D, Carpenter R, Vinnicombe S, Gallagher CJ (2008) Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer 98(2):289–293PubMedCrossRef

34.

Segara D, Krop IE, Garber JE et al (2007) Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96(6):474–480PubMedCrossRef

35.

Hsiang DJ, Yamamoto M, Mehta RS, Su MY, Baick CH, Lane KT, Butler JA (2007) Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Arch Surg 142(9):855–861 discussion 860–861PubMedCrossRef

36.

Garimella V, Qutob O, Fox JN, Long ED, Chaturvedi A, Turnbull LW, Drew PJ (2007) Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol 33(2):157–161PubMedCrossRef

37.

Belli P, Costantini M, Malaspina C, Magistrelli A, Latorre G, Bonomo L (2006) MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 61(11):946–953PubMedCrossRef

38.

Akazawa K, Tamaki Y, Taguchi T et al (2006) Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 12(2):130–137PubMedCrossRef

39.

Yeh E, Slanetz P, Kopans DB et al (2005) Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 184(3):868–877PubMed

40.

Schott AF, Roubidoux MA, Helvie MA et al (2005) Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat 92(3):231–238PubMedCrossRef

41.

Warren RM, Bobrow LG, Earl HM et al (2004) Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 90(7):1349–1360PubMedCrossRef

42.

Martincich L, Montemurro F, De Rosa G et al (2004) Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83(1):67–76PubMedCrossRef

43.

Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C (2004) Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvantchemotherapy. Eur Radiol 14(8):1371–1379PubMedCrossRef

44.

Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L (2004) Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30(10):1069–1076PubMedCrossRef

45.

Bodini M, Berruti A, Bottini A et al (2004) Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Res Treat 85(3):211–218PubMedCrossRef

46.

Wasser K, Sinn HP, Fink C et al (2003) Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 13(6):1213–1223PubMed

47.

Rosen EL, Blackwell KL, Baker JA et al (2003) Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 181(5):1275–1282PubMed

48.

Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Kopans DB, Garrido L (2003) Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. Radiology 228(1):63–69PubMedCrossRef

49.

Cheung YC, Chen SC, Su MY et al (2003) Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI. Breast Cancer Res Treat 78(1):51–58PubMedCrossRef

50.

Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T (2002) Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 12(7):1711–1719PubMedCrossRef

51.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179(5):1193–1199PubMed

52.

Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R (2002) Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 72(2):145–152PubMedCrossRef

53.

Esserman L, Kaplan E, Partridge S et al (2001) MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8(6):549–559PubMedCrossRef

54.

Jaeschke R, Guyatt GH, Sackett DL (1994) Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 271:703–707PubMedCrossRef

55.

Yuan Y, Chen XS, Liu SY, Shen KW (2010) Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. AJR Am J Roentgenol 195(1):260–268PubMedCrossRef

Title: Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?
Authors: Lian-Ming Wu
Jia-Ni Hu
Hai-Yan Gu
Jia Hua
Jie Chen
Jian-Rong Xu
Publication date: 01-08-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2033-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences

BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

Nuclear nano-morphology markers of histologically normal cells detect the “field effect” of breast cancer

Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression

Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer